Unknown

Dataset Information

0

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.


ABSTRACT:

Purpose

Nivolumab is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC).

Patients and methods

Patients with clear-cell mRCC previously treated with agents targeting the vascular endothelial growth factor pathway were randomly assigned (blinded ratio of 1:1:1) to nivolumab 0.3, 2, or 10 mg/kg intravenously once every 3 weeks. The primary objective was to evaluate the dose-response relationship as measured by progression-free survival (PFS); secondary end points included objective response rate (ORR), overall survival (OS), and safety.

Results

A total of 168 patients were randomly assigned to the nivolumab 0.3- (n = 60), 2- (n = 54), and 10-mg/kg (n = 54) cohorts. One hundred eighteen patients (70%) had received more than one prior systemic regimen. Median PFS was 2.7, 4.0, and 4.2 months, respectively (P = .9). Respective ORRs were 20%, 22%, and 20%. Median OS was 18.2 months (80% CI, 16.2 to 24.0 months), 25.5 months (80% CI, 19.8 to 28.8 months), and 24.7 months (80% CI, 15.3 to 26.0 months), respectively. The most common treatment-related adverse event (AE) was fatigue (24%, 22%, and 35%, respectively). Nineteen patients (11%) experienced grade 3 to 4 treatment-related AEs.

Conclusion

Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC. No dose-response relationship was detected as measured by PFS. These efficacy and safety results in mRCC support study in the phase III setting.

SUBMITTER: Motzer RJ 

PROVIDER: S-EPMC4806782 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8462641 | biostudies-literature
| S-EPMC6524207 | biostudies-literature
| S-EPMC6476457 | biostudies-literature
| S-EPMC6693716 | biostudies-literature
| S-EPMC9365340 | biostudies-literature
| S-EPMC4526387 | biostudies-literature
| S-EPMC6445699 | biostudies-literature
| S-EPMC5106340 | biostudies-literature
| S-EPMC10172300 | biostudies-literature
| S-EPMC10994246 | biostudies-literature